Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Talwani

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|February 21, 2018
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysisTarik Asselah, Hendrik Reesink, Jan Gerstoft, et al.
Journal of Gastroenterology and Hepatology|February 20, 2019
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infectionLai Wei, Hiromitsu Kumada, Ponni V Perumalswami, et al.
Hepatology (Baltimore, Md.)|March 4, 2017
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III StudyChristophe Hézode, Massimo Colombo, Marc Bourlière, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2006
Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremiaJ John Weems, James P Steinberg, Scott Filler, et al.
Hepatology Communications|May 16, 2018
Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infectionJacob George, Eduard Burnevich, I-Shyan Sheen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 26, 2019
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized studyTarik Asselah, Stanislas Pol, Christophe Hezode, et al.
Journal of Gastroenterology and Hepatology|October 13, 2018
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL studyLai Wei, Ji Dong Jia, Fu Sheng Wang, et al.
JAMA|February 24, 2015
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infectionAnu Osinusi, Kerry Townsend, Anita Kohli, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|December 15, 2020
Efficacy and safety of elbasvir/grazoprevir in treatment-naive Chinese adults with hepatitis C virus infection: A randomized trialLai Wei, Ji Dong Jia, Zhong Ping Duan, et al.
JAMA|August 29, 2013
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trialAnuoluwapo Osinusi, Eric G Meissner, Yu-Jin Lee, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Liver International : Official Journal of the International Association for the Study of the Liver|February 21, 2018
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysisTarik Asselah, Hendrik Reesink, Jan Gerstoft, et al.
Journal of Gastroenterology and Hepatology|February 20, 2019
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infectionLai Wei, Hiromitsu Kumada, Ponni V Perumalswami, et al.
Hepatology (Baltimore, Md.)|March 4, 2017
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III StudyChristophe Hézode, Massimo Colombo, Marc Bourlière, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2006
Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremiaJ John Weems, James P Steinberg, Scott Filler, et al.
Hepatology Communications|May 16, 2018
Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infectionJacob George, Eduard Burnevich, I-Shyan Sheen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 26, 2019
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized studyTarik Asselah, Stanislas Pol, Christophe Hezode, et al.
Journal of Gastroenterology and Hepatology|October 13, 2018
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL studyLai Wei, Ji Dong Jia, Fu Sheng Wang, et al.
JAMA|February 24, 2015
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infectionAnu Osinusi, Kerry Townsend, Anita Kohli, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|December 15, 2020
Efficacy and safety of elbasvir/grazoprevir in treatment-naive Chinese adults with hepatitis C virus infection: A randomized trialLai Wei, Ji Dong Jia, Zhong Ping Duan, et al.
JAMA|August 29, 2013
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trialAnuoluwapo Osinusi, Eric G Meissner, Yu-Jin Lee, et al.
Pageof 5